메뉴 건너뛰기




Volumn 9, Issue , 2016, Pages 1571-1578

The efficacy and safety of nivolumab in the treatment of advanced melanoma: A meta-analysis of clinical trials

Author keywords

Advanced melanoma; Meta analysis; Nivolumab

Indexed keywords

IPILIMUMAB; NIVOLUMAB;

EID: 84961266555     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S96762     Document Type: Article
Times cited : (12)

References (35)
  • 1
    • 84983373947 scopus 로고    scopus 로고
    • [homepage on the Internet], melanoma version 3.2015. NCCN; 2015, Accessed February 3
    • ®): melanoma version 3.2015. NCCN; 2015. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed February 3, 2016.
    • (2016) ®)
  • 3
    • 84870878674 scopus 로고    scopus 로고
    • Management options for metastatic melanoma in the era of novel therapies: A primer for the practicing dermatologist: Part II: Management of stage IV disease
    • Fox MC, Lao CD, Schwartz JL, et al. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: management of stage IV disease. J Am Acad Dermatol. 2013;68(1):13.e1–13.
    • (2013) J am Acad Dermatol , vol.68 , Issue.1 , pp. 13.e1-13.e13
    • Fox, M.C.1    Lao, C.D.2    Schwartz, J.L.3
  • 4
    • 84886895936 scopus 로고    scopus 로고
    • [homepage on the Internet], WHO, Accessed February 3
    • World Health Organization [homepage on the Internet]. Ultraviolet radiation and the INTERSUN Programme. WHO; 2012. Available from: http://www.who.int/uv/en/. Accessed February 3, 2016.
    • (2012) Ultraviolet Radiation and the INTERSUN Programme
  • 5
    • 84866600895 scopus 로고    scopus 로고
    • Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • Dummer R, Hauschild A, Guggenheim M, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii86–vii91.
    • (2012) Ann Oncol , vol.23 , pp. vii86-vii91
    • Dummer, R.1    Hauschild, A.2    Guggenheim, M.3
  • 6
    • 84934897714 scopus 로고    scopus 로고
    • Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
    • Niezgoda A, Niezgoda P, Czajkowski R. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int. 2015;2015:851387.
    • (2015) Biomed Res Int , vol.2015
    • Niezgoda, A.1    Niezgoda, P.2    Czajkowski, R.3
  • 7
    • 84901640582 scopus 로고    scopus 로고
    • Recent developments in the medical and surgical treatment of melanoma
    • Saranga-Perry V, Ambe C, Zager JS, Kudchadkar RR. Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin. 2014;64(3):171–185.
    • (2014) CA Cancer J Clin , vol.64 , Issue.3 , pp. 171-185
    • Saranga-Perry, V.1    Ambe, C.2    Zager, J.S.3    Kudchadkar, R.R.4
  • 8
    • 84929223574 scopus 로고    scopus 로고
    • Immunologic correlates in the course of treatment with immunomodulating antibodies
    • Weide B, Di Giacomo AM, Fonsatti E, Zitvogel L. Immunologic correlates in the course of treatment with immunomodulating antibodies. Semin Oncol. 2015;42(3):448–458.
    • (2015) Semin Oncol , vol.42 , Issue.3 , pp. 448-458
    • Weide, B.1    Di Giacomo, A.M.2    Fonsatti, E.3    Zitvogel, L.4
  • 9
    • 84924272311 scopus 로고    scopus 로고
    • PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
    • Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479–3492.
    • (2015) Oncotarget , vol.6 , Issue.6 , pp. 3479-3492
    • Luke, J.J.1    Ott, P.A.2
  • 10
    • 84919682995 scopus 로고    scopus 로고
    • Immuno-oncology combinations: A review of clinical experience and future prospects
    • Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res. 2014;20(24):6258–6268.
    • (2014) Clin Cancer Res , vol.20 , Issue.24 , pp. 6258-6268
    • Antonia, S.J.1    Larkin, J.2    Ascierto, P.A.3
  • 11
    • 84922004360 scopus 로고    scopus 로고
    • Clinical impact of checkpoint inhibitors as novel cancer therapies
    • Shih K, Arkenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs. 2014;74(17):1993–2013.
    • (2014) Drugs , vol.74 , Issue.17 , pp. 1993-2013
    • Shih, K.1    Arkenau, H.T.2    Infante, J.R.3
  • 12
    • 84939967609 scopus 로고    scopus 로고
    • The role of anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
    • Tsai KK, Daud AI. The role of anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs. 2015;75(6):563–575.
    • (2015) Drugs , vol.75 , Issue.6 , pp. 563-575
    • Tsai, K.K.1    Daud, A.I.2
  • 13
    • 84896714827 scopus 로고    scopus 로고
    • Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study
    • McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–332.
    • (2014) Lancet Oncol , vol.15 , Issue.3 , pp. 323-332
    • McArthur, G.A.1    Chapman, P.B.2    Robert, C.3
  • 14
    • 84863673204 scopus 로고    scopus 로고
    • Improved survival with MEK inhibition in BRAF-mutated melanoma
    • Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–114.
    • (2012) N Engl J Med , vol.367 , Issue.2 , pp. 107-114
    • Flaherty, K.T.1    Robert, C.2    Hersey, P.3
  • 15
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
    • Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
    • (2012) Lancet , vol.380 , Issue.9839 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3
  • 16
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    • Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–714.
    • (2012) N Engl J Med , vol.366 , Issue.8 , pp. 707-714
    • Sosman, J.A.1    Kim, K.B.2    Schuchter, L.3
  • 17
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
    • (2011) N Engl J Med , vol.364 , Issue.26 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 18
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
    • (2010) N Engl J Med , vol.363 , Issue.8 , pp. 711-723
    • Hodi, F.S.1    O’Day, S.J.2    McDermott, D.F.3
  • 19
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526.
    • (2011) N Engl J Med , vol.364 , Issue.26 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3
  • 20
    • 84920031180 scopus 로고    scopus 로고
    • In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates
    • Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–856.
    • (2014) Cancer Immunol Res , vol.2 , Issue.9 , pp. 846-856
    • Wang, C.1    Thudium, K.B.2    Han, M.3
  • 21
    • 84929156397 scopus 로고    scopus 로고
    • Toxicity patterns with immunomodulating antibodies and their combinations
    • Haanen JB, Thienen HV, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol. 2015;42(3):423–428.
    • (2015) Semin Oncol , vol.42 , Issue.3 , pp. 423-428
    • Haanen, J.B.1    Thienen, H.V.2    Blank, C.U.3
  • 22
    • 84898973055 scopus 로고    scopus 로고
    • Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
    • Topalian SL, Mario S, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030.
    • (2014) J Clin Oncol , vol.32 , Issue.10 , pp. 1020-1030
    • Topalian, S.L.1    Mario, S.2    McDermott, D.F.3
  • 23
    • 84859158384 scopus 로고    scopus 로고
    • Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity
    • Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207–212.
    • (2012) Curr Opin Immunol , vol.24 , Issue.2 , pp. 207-212
    • Topalian, S.L.1    Drake, C.G.2    Pardoll, D.M.3
  • 24
    • 84936147067 scopus 로고    scopus 로고
    • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
    • Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34.
    • (2015) N Engl J Med , vol.373 , Issue.1 , pp. 23-34
    • Larkin, J.1    Chiarion-Sileni, V.2    Gonzalez, R.3
  • 25
    • 84929481482 scopus 로고    scopus 로고
    • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
    • Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017.
    • (2015) N Engl J Med , vol.372 , Issue.21 , pp. 2006-2017
    • Postow, M.A.1    Chesney, J.2    Pavlick, A.C.3
  • 26
    • 84925222119 scopus 로고    scopus 로고
    • Nivolumab in previously untreated melanoma without BRAF mutation
    • Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.
    • (2015) N Engl J Med , vol.372 , Issue.4 , pp. 320-330
    • Robert, C.1    Long, G.V.2    Brady, B.3
  • 27
    • 84931083080 scopus 로고    scopus 로고
    • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial
    • Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384.
    • (2015) Lancet Oncol , vol.16 , Issue.4 , pp. 375-384
    • Weber, J.S.1    D’Angelo, S.P.2    Minor, D.3
  • 28
    • 0033610734 scopus 로고    scopus 로고
    • Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement
    • Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet. 1999;354(9193):1896–1900.
    • (1999) Lancet , vol.354 , Issue.9193 , pp. 1896-1900
    • Moher, D.1    Cook, D.J.2    Eastwood, S.3
  • 30
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    • Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
    • (2009) Eur J Cancer , vol.45 , Issue.2 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 31
    • 84996528887 scopus 로고    scopus 로고
    • Treatment options expanding for advanced melanoma
    • Thompson JA. Treatment options expanding for advanced melanoma. J Natl Compr Canc Netw. 2015;13(5 Suppl):673–675.
    • (2015) J Natl Compr Canc Netw , vol.13 , Issue.5 , pp. 673-675
    • Thompson, J.A.1
  • 32
    • 84929178180 scopus 로고    scopus 로고
    • The ipilimumab lesson in melanoma: Achieving long-term survival
    • Delyon J, Maio M, Lebbé C. The ipilimumab lesson in melanoma: achieving long-term survival. Semin Oncol. 2015;42(3):387–401.
    • (2015) Semin Oncol , vol.42 , Issue.3 , pp. 387-401
    • Delyon, J.1    Maio, M.2    Lebbé, C.3
  • 33
    • 84878432797 scopus 로고    scopus 로고
    • Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival
    • Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013;24(6):1697–1703.
    • (2013) Ann Oncol , vol.24 , Issue.6 , pp. 1697-1703
    • Delyon, J.1    Mateus, C.2    Lefeuvre, D.3
  • 34
    • 84901246811 scopus 로고    scopus 로고
    • Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort
    • Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014;12(1):116.
    • (2014) J Transl Med , vol.12 , Issue.1
    • Ascierto, P.A.1    Simeone, E.2    Sileni, V.C.3
  • 35
    • 84876678621 scopus 로고    scopus 로고
    • Patterns of onset and resolution of immune–related adverse events of special interest with ipilimumab
    • Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune–related adverse events of special interest with ipilimumab. Cancer. 2013;119(9):1675–1682.
    • (2013) Cancer , vol.119 , Issue.9 , pp. 1675-1682
    • Weber, J.S.1    Dummer, R.2    De Pril, V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.